In response, a comprehensive range of small molecules as drugs that are already in clinical applications for treating various diseases might specifically target Sirt2 directly; and hence, stimulate approaches in treatment for Sirt2 associated diseases such as cancer and neurodegeneration via an approach referred to as drug repurposing or repositioning. Here, SIRT2 is linked to cancer.